Agencies
Ex-HHS Workers Accuse Trump Administration of Using Flawed Data to Justify Mass Firings
HHS firings; Trump administration; federal workforce; flawed data; Project 2025; agency cuts; disability services; Medicare; public servants
FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts
United States Food and Drug Administration, PDUFA, Impact food supplement, Approved, Agencies, questions
FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies
Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire
Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format
Senate confirms Johns Hopkins surgeon Marty Makary to lead FDA amid turbulence at the agency
Makary, Senate, United States Food and Drug Administration, Surgeon, Johns, Agencies, Dr., Marty
EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION
Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation
European Medicines Agency Investigates Potential Link Between Hair Loss Drugs and Suicidal Thoughts
EMA, hair loss drugs, finasteride, dutasteride, suicidal thoughts, psychiatric side effects, European Medicines Agency
Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment
Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency
EU Regulatory Panel Rejects Eisai and Biogen’s Leqembi for Alzheimer’s Treatment
Leqembi, Alzheimer’s disease, Eisai, Biogen, European Medicines Agency, regulatory panel, approval rejection, adverse effects
European Regulators Reject Eisai and Biogen’s Alzheimer’s Drug Leqembi
Eisai, Biogen, Leqembi, Alzheimer’s disease, European Medicines Agency, drug rejection